Brainstorm Cell Therapeutics Inc

Healthcare US BCLI

0.91USD
0.00(0%)

Last update at 2026-06-23T20:00:00Z

Day Range

0.880.93

LowHigh

52 Week Range

0.461.92

LowHigh

Fundamentals

Previous Close 0.91
Market Cap9.60M
Volume7727
P/E Ratio-
Dividend Yield-%
EBITDA-9.75400M
Revenue TTM0.00000M
Revenue Per Share TTM-
Gross Profit TTM 0.00000M
Diluted EPS TTM-1.08

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Income before tax	-10.30700M	11.62M	-17.19200M	-24.27700M	-24.45700M
Minority interest	-	-	-	-	-
Net income	-10.30700M	11.62M	-17.19200M	-23.73200M	-24.37500M
Selling general administrative	5.78M	7.04M	10.69M	10.87M	9.30M
Selling and marketing expenses	-	-	10.68M	-	-
Gross profit	-	-0.24000M	-0.26500M	-	-
Reconciled depreciation	0.20M	0.24M	0.27M	0.28M	0.26M
Ebit	-9.95300M	-11.54600M	-17.19200M	-25.10700M	-24.53900M
Ebitda	-9.75400M	-11.30600M	-16.92700M	-24.82200M	-24.27900M
Depreciation and amortization	0.20M	0.24M	0.27M	0.28M	0.26M
Non operating income net other	-	-	-	-	-
Operating income	-9.95300M	-11.69300M	-21.43900M	-24.82200M	-24.53900M
Other operating expenses	9.95M	11.69M	21.44M	24.82M	24.54M
Interest expense	-	0.08M	-	-0.54500M	0.08M
Tax provision	-	-	-	-	-
Interest income	-	-	-	0.55M	-
Net interest income	-0.53300M	-0.07700M	-0.01200M	0.55M	0.08M
Extraordinary items	-	-	-	-	-
Non recurring	-	-	-	-	-
Other items	-	-	-	-	-
Income tax expense	-	11.62M	-	-0.54500M	-0.08200M
Total revenue	0.70M	0.85M	0.00000M	0.00000M	0.00000M
Total operating expenses	9.95M	11.69M	21.17M	24.82M	24.54M
Cost of revenue	-	0.24M	0.27M	-	-
Total other income expense net	-0.35400M	0.07M	4.25M	0.55M	0.08M
Discontinued operations	-	-	-	-	-
Net income from continuing ops	-10.30700M	-11.62300M	-16.63200M	-24.27700M	-24.45700M
Net income applicable to common shares	-	-	-	-24.27700M	-24.45700M
Preferred stock and other adjustments	-	-	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total assets	0.71M	1.83M	4.21M	8.45M	29.28M
Intangible assets	-	-	0.00300M	-	-
Earning assets	-	-	-	-	-
Other current assets	0.19M	0.14M	0.55M	0.03M	1.10M
Total liab	11.01M	9.60M	9.07M	11.47M	9.94M
Total stockholder equity	-10.29200M	-7.76400M	-4.85800M	-3.01500M	19.34M
Deferred long term liab	-	-	-	-	-
Other current liab	3.94M	2.35M	2.24M	0.08M	0.08M
Common stock	0.02M	0.01M	0.01M	0.01M	0.01M
Capital stock	0.02M	0.01M	-	0.01M	0.01M
Retained earnings	-236.94300M	-226.63600M	-215.01300M	-197.82100M	-173.54400M
Other liab	-	-	-	-	-
Good will	-	-	-	-	-
Other assets	-	-	-	0.02M	0.03M
Cash	0.03M	0.19M	1.30M	0.77M	18.86M
Cash and equivalents	-	-	-	-	-
Total current liabilities	11.01M	8.98M	7.80M	8.80M	6.32M
Current deferred revenue	-	-	-	-	-
Net debt	0.18M	0.53M	-0.02500M	3.32M	-13.77700M
Short term debt	-	0.55M	0.60M	1.43M	1.46M
Short long term debt	-	-	-	-	-
Short long term debt total	0.21M	0.72M	1.27M	4.09M	5.08M
Other stockholder equity	226.94M	218.86M	210.14M	194.79M	192.87M
Property plant equipment	-	-	-	5.31M	5.97M
Total current assets	0.31M	0.39M	1.90M	3.11M	23.28M
Long term investments	-	-	-	-	-
Net tangible assets	-	-	-	-3.02400M	19.34M
Short term investments	-	-	-	2.21M	3.24M
Net receivables	0.09M	0.06M	0.05M	0.09M	0.09M
Long term debt	-	-	-	-	-
Inventory	-	-	-	-	-
Accounts payable	7.07M	6.08M	4.95M	7.29M	4.77M
Total permanent equity	-	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-	-
Accumulated other comprehensive income	-	-	0.00000M	-	-
Additional paid in capital	-	-	-	-	-
Common stock total equity	-	-	-	-	0.01M
Preferred stock total equity	-	-	-	-	-
Retained earnings total equity	-	-	-	-	-173.54400M
Treasury stock	-	-	-	-	-
Accumulated amortization	-	-	-	-	-
Non currrent assets other	-0.28200M	0.02M	0.02M	0.02M	0.03M
Deferred long term asset charges	-	-	-	-	-
Non current assets total	0.41M	1.45M	2.31M	5.34M	6.00M
Capital lease obligations	0.21M	0.72M	-	4.09M	5.08M
Long term debt total	-	-	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Investments	0.00000M	0.01M	3.04M	1.00M	0.65M
Change to liabilities	-	-	-	2.52M	-1.71700M
Total cashflows from investing activities	-	0.01M	2.19M	1.00M	0.32M
Net borrowings	0.58M	0.00000M	-	-	-
Total cash from financing activities	6.88M	7.97M	18.98M	0.24M	6.97M
Change to operating activities	-	-	-	-0.60100M	-2.05200M
Net income	-10.30700M	-11.62300M	-17.19200M	-24.27700M	-24.45700M
Change in cash	-0.09500M	-1.11400M	0.71M	-18.08400M	-18.97300M
Begin period cash flow	0.37M	1.49M	0.77M	18.86M	37.83M
End period cash flow	0.28M	0.37M	1.49M	0.77M	18.86M
Total cash from operating activities	-6.97500M	-9.09300M	-20.45800M	-19.32000M	-26.26500M
Issuance of capital stock	4.35M	7.97M	15.86M	0.24M	6.96M
Depreciation	0.20M	0.24M	0.27M	0.28M	0.26M
Other cashflows from investing activities	-	0.01M	2.21M	-	-
Dividends paid	-	-	-	-	-
Change to inventory	-	-	-	-	-
Change to account receivables	-0.08300M	0.40M	-0.47500M	1.07M	0.34M
Sale purchase of stock	-	-	-	-	0.00500M
Other cashflows from financing activities	0.45M	-	2.19M	1.00M	0.00500M
Change to netincome	-	-	-	1.68M	1.37M
Capital expenditures	0.00000M	0.00000M	0.02M	0.03M	0.33M
Change receivables	-	-	-	-	0.34M
Cash flows other operating	-	-	-	-	-0.04700M
Exchange rate changes	-	-	-	-	-
Cash and cash equivalents changes	-	-	-	-	-18.97300M
Change in working capital	1.79M	1.69M	-0.49600M	2.99M	-3.43400M
Stock based compensation	1.52M	0.75M	1.49M	1.68M	1.37M
Other non cash items	-0.17900M	-0.14700M	-4.52500M	-	3.43M
Free cash flow	-6.97500M	-9.09300M	-20.47600M	-19.34900M	-26.59500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company	Change (USD)	Price (USD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to EBITDA (x)
BCLI Brainstorm Cell Therapeutics Inc	- -%	0.91	-	-	625.19	54.50	-1.7036
NVO Novo Nordisk A/S	0.09 0.19%	47.51	41.58	31.15	2.13	32.99	2.11	4.70
NONOF Novo Nordisk A/S	- -%	46.84	41.06	31.25	2.08	33.11	2.11	4.70
VRTX Vertex Pharmaceuticals Inc	8.43 1.80%	476.85	29.67	24.33	10.38	5.83	9.33	20.00
REGN Regeneron Pharmaceuticals Inc	3.79 0.61%	621.82	29.07	20.12	7.57	3.82	6.95	19.42

Reports Covered

View All

Profile

Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Brainstorm Cell Therapeutics Inc

1325 Avenue of Americas, New York, NY, United States, 10019

201 488 0460
https://www.brainstorm-cell.com
Employees : 20

Key Executives

Name	Title	Year Born
Mr. Chaim Lebovits	Chief Exec. Officer	1971
Dr. Irit Arbel DSc, Ph.D.	Co-Founder & Independent Vice Chair of the Board	1960
Dr. Ralph Z. Kern	Pres & Chief Medical Officer	1958
Dr. Stacy R. Lindborg Ph.D.	Exec. VP & Chief Devel. Officer	1971
Mr. Uri Yablonka	Exec. VP, Chief Bus. Officer, Sec. & Director	1977
Ms. Alla Patlis CPA, M.B.A.	Controller & Interim CFO	1987
Dr. David Setboun M.B.A., Pharm.D.	Exec. VP & COO	1975
Dr. Yael Gothelf	VP of Scientific & Regulatory Affairs	NA
Ms. Antal Pearl-Lendner	VP & Chief Legal Counsel	NA
Dr. Daniel Offen Ph.D.	Chief Scientific Advisor	NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.